- Diagnostics company Veracyte becomes the latest firm looking to take advantage of the hot market for biotech IPOs, filing to raise up to $74.75M in a listing on Nasdaq, where it plans to trade under the ticker symbol "VCYT."
- Veracyte's first product is the Afirma Thyroid FNA Analysis, which can check whether thyroid nodules can be classified as non-cancerous. The company has granted Genzyme the rights to market Afirma Thyroid FNA Analysis.
- In H1, Veracyte generated revenues of $9.5M vs $11.6M for the whole of 2012. (PR)
Veracyte files for $74.75M IPO
Sep 23 2013, 10:12 ET